NYSEAMERICAN:NAVB

Navidea Biopharmaceuticals Stock Forecast, Price & News

$1.71

-0.01 (-0.58 %)

(As of 07/28/2021 03:17 PM ET)

Add

Compare

Today's Range

$1.69

▼

$1.71

50-Day Range

$1.88

▼

$2.33

52-Week Range

$1.46

▼

$5.02

Volume334 shs

Average Volume252,817 shs

Market Capitalization$49.63 million

P/E RatioN/A

Dividend YieldN/A

Beta1.73

30 days | 90 days | 365 days | Advanced Chart

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) Director Malcolm G. Witter Buys 15,000 Shares
July 26, 2021 | americanbankingnews.com

Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications
July 19, 2021 | finance.yahoo.com

Navidea Biopharmaceuticals, FDA to Meet on Rheumatoid Arthritis Treatment
July 17, 2021 | marketwatch.com

Navidea Stock Gains After FDA Grants End Of Phase 2 Meeting To Discuss Rheumatoid Arthritis Program
July 15, 2021 | msn.com

BRIEF-Navidea Biopharmaceuticals Announces End-Of-Phase 2 Type B Meeting Request Granted By The FDA To Discuss Ongoing Clinical Program In Rheumatoid Arthritis
July 15, 2021 | msn.com

Navidea Biopharma : FDA Meeting On Rheumatoid Arthritis To Take Place On Sept 1
July 15, 2021 | markets.businessinsider.com

Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis
July 15, 2021 | finance.yahoo.com

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) Sees Significant Increase in Short Interest
July 3, 2021 | americanbankingnews.com

NAVB Aug 2021 3.000 call
July 1, 2021 | sg.finance.yahoo.com

NAVB Oct 2021 2.000 put
July 1, 2021 | sg.finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSEAMERICAN:NAVB
Previous SymbolNYSEMKT:NAVB
CUSIP63937X10
CIK810509
Webwww.navidea.com
Phone+1-614-7937500
Employees13
Year FoundedN/A

Sales & Book Value

Annual Sales$920,000.00
Price / Sales53.95
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.46 per share
Price / Book3.72

Profitability

EPS (Most Recent Fiscal Year)($0.48)
Net Income$-10,720,000.00
Net Margins-1,248.87%
Return on Equity-109.24%
Return on Assets-142.41%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares29,025,000
Market Cap$49.63 million
Next Earnings Date8/12/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.84 out of 5 stars

Medical Sector

485th out of 2,210 stocks

Diagnostic Substances Industry

7th out of 38 stocks

3.5 Analyst's Opinion

Consensus Rating
Navidea Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.50, Navidea Biopharmaceuticals has a forecasted upside of 338.6% from its current price of $1.71.
Amount of Analyst Coverage
Navidea Biopharmaceuticals has received no research coverage in the past 90 days.

3.4 Community Rank

Outperform Votes
Navidea Biopharmaceuticals has received 191 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Navidea Biopharmaceuticals has received 87 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Navidea Biopharmaceuticals has received 68.71% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote “Outperform” if you believe NAVB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Navidea Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
Navidea Biopharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Navidea Biopharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.49% of the stock of Navidea Biopharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 6.45% of the stock of Navidea Biopharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Navidea Biopharmaceuticals are expected to grow in the coming year, from ($0.37) to ($0.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Navidea Biopharmaceuticals is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Navidea Biopharmaceuticals is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Navidea Biopharmaceuticals has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

Is Navidea Biopharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Navidea Biopharmaceuticals stock.
View analyst ratings for Navidea Biopharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Navidea Biopharmaceuticals?

Wall Street analysts have given Navidea Biopharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Navidea Biopharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 181,000 shares, an increase of 30.2% from the May 31st total of 139,000 shares. Based on an average daily volume of 193,700 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.9% of the company's stock are short sold.
View Navidea Biopharmaceuticals' Short Interest.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Navidea Biopharmaceuticals.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) released its quarterly earnings results on Monday, May, 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.60 million. Navidea Biopharmaceuticals had a negative trailing twelve-month return on equity of 109.24% and a negative net margin of 1,248.87%.
View Navidea Biopharmaceuticals' earnings history.

How has Navidea Biopharmaceuticals' stock been impacted by COVID-19?

Navidea Biopharmaceuticals' stock was trading at $0.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NAVB stock has increased by 78.1% and is now trading at $1.71.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for NAVB?

2 brokers have issued 12 month price targets for Navidea Biopharmaceuticals' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Navidea Biopharmaceuticals' stock price to reach $7.50 in the next year. This suggests a possible upside of 338.6% from the stock's current price.
View analysts' price targets for Navidea Biopharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the following people:

Mr. Jed A. Latkin, CEO, COO, CFO & Director (Age 47, Pay $739.99k)
Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer (Age 52, Pay $282.45k)
Erika Gibson, Director of Fin. & Admin.
Mr. William J. Regan, Chief Compliance Officer (Age 69)

Who are some of Navidea Biopharmaceuticals' key competitors?

Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), STERIS (STE) and Insulet (PODD).
View all of NAVB's competitors.

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), CorMedix (CRMD), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $1.71.

How much money does Navidea Biopharmaceuticals make?

Navidea Biopharmaceuticals has a market capitalization of $49.63 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-10,720,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Navidea Biopharmaceuticals have?

Navidea Biopharmaceuticals employs 13 workers across the globe.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is www.navidea.com.

Where are Navidea Biopharmaceuticals' headquarters?

Navidea Biopharmaceuticals is headquartered at 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500 or via email at [email protected]

This page was last updated on 7/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here